BROOMFIELD, Colo. — May 5, 2026 — Leads & Copy — Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company, has established a second commercial agreement with Weill Cornell Medicine to bring its Nociscan platform to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center.
The trial, led by neurosurgeon Roger Härtl, MD, will evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate (BMAC) injection on patient reported outcomes. The study, entitled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial,” is conducted under IRB Protocol No. 24-09027977.
The study also aims to learn more about the natural history of degenerative disc disease (DDD) and inform its treatments. Aclarion’s Nociscan platform leverages biomarkers and augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain and support improved treatment success rates.
“Our scientific interest focuses on clinical and basic science research surrounding innovative and less invasive surgical and biological treatment strategies for degenerative diseases of the spine,” said Dr. Härtl, the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at Weill Cornell Medicine in New York. He also serves as a paid consultant for Aclarion. “This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging.”
Ryan Bond, Chief Strategy Officer of Aclarion, said the company is pleased to engage in this trial with Dr. Härtl and his team. He added that progressive trials like this are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.
Approximately 266 million people worldwide suffer from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
Nociscan objectively quantifies chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive discs are treated.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain.
When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
Source: Aclarion, Inc.
